BioSpace News Archive

Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it has been issued a trademark registration for RECCE® from the Intellectual Property Office of Vietnam, strengthening the Company’s global intellectual property portfolio.

Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”) announced today an abstract highlighting long-term survival data from the Company’s ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome (HLHS) has been accepted for presentation as a poster at the upcoming meeting of the American Heart Association (AHA).

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will present a corporate update at the H.C. Wainwright 25th Annual Global Investment Conference, which will take place at the Lotte New York Palace Hotel in New York City, NY Sep 11-13.

Ardelyx, Inc. announced that on September 6, 2023, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 65,828 shares of the company’s common stock, and granted three new non-executive employees an aggregate of 39,550 Restricted Stock Units.

alveofit® (Roundworks Technologies Private Limited) is thrilled to announce that its groundbreaking product, alveoair® spirometer, has earned U.S. FDA clearance for distribution in the United States.

Shoreline Biosciences, Inc. announced a major milestone in its patent litigation with Fate Therapeutics, Inc. and the Whitehead Institute in the U.S. District Court for the Southern District of California.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy.

BlueWhale Bio Science Team led by world-renowned immunotherapy pioneers Carl June and James Riley of University of Pennsylvania BlueWhale Bio technology platform aims to bring cell and gene therapy benefits to patients faster and at lower cost Investors include Danaher Ventures, Novalis LifeSciences, Marshall Wace , Hillhouse Capital.

Intensity Therapeutics, Inc. today announced that the US Food and Drug Administration’s Office of Orphan Products Development has granted orphan-drug designation for the treatment of soft tissue sarcoma (STS) to the three active moieties comprising INT230-6, cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO-FA (8-((2-hydroxybenzoyl) amino)octanoate).

Harmony Biosciences Holdings, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia (IH).